To include your compound in the COVID-19 Resource Center, submit it here.

Celyad’s CAR T leads to leukemia-free state in AML patient

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said a patient with acute myelogenous leukemia (AML) achieved a morphologic leukemia-free state (MLFS) after receiving the company's chimeric antigen receptor

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE